Hospital admission of high risk infants for respiratory syncytial virus infection: Implications for palivizumab prophylaxis

Archives of Disease in Childhood: Fetal and Neonatal Edition

Volumn 90, Issue 1, 2005, Pages

  Heikkinen, T ^a   Valkonen, H ^a   Lehtonen, L ^a   Vainionpaa R ^a   Ruuskanen, O ^a  

^a TURKU UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

PALIVIZUMAB;

ARTICLE; CHILD; COHORT ANALYSIS; HIGH RISK PATIENT; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROPHYLAXIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY TRACT INFECTION; RETROSPECTIVE STUDY; UNIVERSITY HOSPITAL;

ANTIBODIES, MONOCLONAL; ANTIVIRAL AGENTS; FINLAND; GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INTENSIVE CARE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SEASONS;

EID: 11144333533     PISSN: 13592998     EISSN: 14682052     Source Type: Journal    
DOI: 10.1136/adc.2003.029710     Document Type: Article

References (24)

1. Ruuskanen O, Ogra PL. Respiratory syncytial virus. Curr Probl Pediatr 1993;23:S50-79.
2. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988;82:199-203.
3. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 1991;88:527-32.
4. Englund JA. Prevention strategies for respiratory syncytial virus: passive and active immunization. J Pediatr 1999;135:538-44.
5. Simoes EAF. Respiratory syncytial virus infection. Lancet 1999;354:847-52.
6. Johnson S, Oliver C, Prince GA, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997;176:1215-24.
7. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7.
8. American Academy of Pediatrics. Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 1998;102:1211-16.
9. Joffe S, Escobar GJ, Black SB, et al. Rehospitalization for respiratory syncytial virus among premature infants. Pediatrics 1999;104:894-9.
10. Clark SJ, Beresford MW, Subhedar NV, et al. Respiratory syncytial virus infection in high risk infants and the potential impact of prophylaxis in a United Kingdom cohort. Arch Dis Child 2000;83:313-16.
11. Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants: implications for use of RSV immune globulin. Arch Dis Child 2000;83:122-7.
12. Boyce TG, Mellen BG, Mitchel EF, et al. Rates of hospitalization far respiratory syncytial virus infection among children in Medicaid. J Pediatr 2000;137:865-70.
13. Stevens TP, Sinkin RA, Hall CB, et al. Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier. Arch Pediatr Adolesc Med 2000;154:55-61.
14. Fariña D, Rodriguez SP, Bauer G, et al. Respiratory syncytial virus prophylaxis: cost-effective analysis in Argentina. Pediatr infect Dis J 2002;21:287-91.
15. Moler FW, Brown RW, Faix RG, et al. Comments on palivizumab (Synagis). Pediatrics 1999;103:495-7.
16. Sharland M, Bedford-Russell A. Preventing respiratory syncytial virus bronchiolitis. BMJ 2001;322:62-3.
17. Kamal-Bahl S, Doshi DJ, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med 2002;156:1034-41.
18. McCormick J, Tubman R. Readmission with respiratory syncytial virus (RSV) infection among graduates from a neonatal intensive care unit. Pediatr Pulmonol 2002;34:262-6.
19. Shireman TI, Braman KS. Impact and cost-effectiveness of respiratory syncytial virus prophylaxis for Kansas Medicaid's high-risk children. Arch Pediatr Adolesc Med 2002;156:1251-5.
20. Carbonell-Estrany X, Quero J, IRIS Study Group. Hospitolization rates for respiratory syncytial virus infection in premature infants born during two consecutive seasons. Pediatr Infect Dis J 2001;20:874-9.
21. Waris M, Meurman O, Mufson MA, et al. Shedding of infectious virus and virus antigen during acute infection with respiratory syncytial virus. J Med Virol 1992;38:111-16.
22. Waris M. Pattern of respiratory syncytial virus epidemics in Finland: two-year cycles with alternating prevalence of groups A and B. J Infect Dis 1991;163:464-9.
23. Oh PI, Lanctot KL, Yoon A, et al. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J 2002;21:512-18.
24. Greenough A, Cox S, Alexander J, et al. Health care utilisation of infants with chronic lung disease, related to hospitalisation for RSV infection. Arch Dis Child 2001;85:443-8.